Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer

Trial Profile

Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms FIRE-3
  • Most Recent Events

    • 05 Jun 2018 Results assessing association of efficacy with somatic DNA mutations, tumor mutational burden and MSI status in biomarker evaluable subpopulation (n =373) from this trial, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Results of a genome-wide association study (GWAS) of overall survival (OS) and progression-free survival (PFS) in 790 patients from 3 clinical trials (FIRE-3, TRIBE, and MAVERICC), presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Results (n=451) assessing the polymorphism in the circadian clock pathway for prediction of outcome in patients with metastatic colorectal cancer using genomic DNA from blood samples of patients from TRIBE and FIRE-3 phase III trials, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top